+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Liraglutide"

From
Anti-Obesity Drugs Market Report and Forecast 2024-2032 - Product Thumbnail Image

Anti-Obesity Drugs Market Report and Forecast 2024-2032

  • Report
  • April 2024
  • 160 Pages
  • Global
From
From
Anti-obesity Medication Market - Product Thumbnail Image

Anti-obesity Medication Market

  • Report
  • May 2024
  • 200 Pages
  • Global
From
Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032 - Product Thumbnail Image

Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032

  • Report
  • June 2024
  • 140 Pages
  • Asia Pacific
From
Latin America Anti-Obesity Drugs Market Report and Forecast 2024-2032 - Product Thumbnail Image

Latin America Anti-Obesity Drugs Market Report and Forecast 2024-2032

  • Report
  • June 2024
  • 140 Pages
  • Latin America
From
From
Antiobesity Global Market Report 2024 - Product Thumbnail Image

Antiobesity Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
From
SAXENDA (Liraglutide), Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

SAXENDA (Liraglutide), Drug Insight and Market Forecast - 2032

  • Report
  • September 2022
  • 30 Pages
  • Global
From
From
From
From
From
From
From
From
From
Loading Indicator

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an anti-obesity drug. It is a long-acting analogue of human GLP-1, a hormone that is released in response to food intake. Liraglutide works by stimulating the release of insulin and suppressing appetite. It is typically prescribed as an adjunct to diet and exercise for the treatment of obesity. It is also used to treat type 2 diabetes. Liraglutide is available in both injectable and oral formulations. The injectable form is administered subcutaneously once daily, while the oral form is taken once daily with food. Common side effects of liraglutide include nausea, vomiting, diarrhea, and abdominal pain. Several companies are involved in the liraglutide market, including Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more